Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has signed an exclusive worldwide license agreement with Amgen for the Xeriject formulation of teprotumumab, used for treating Thyroid Eye Disease. Xeris could receive up to $75M in development and regulatory milestones.
January 10, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen enters into a licensing agreement with Xeris for the Xeriject formulation of teprotumumab, expanding its portfolio in treatments for Thyroid Eye Disease.
Amgen's licensing agreement with Xeris allows it to expand its treatment portfolio, which could positively impact its market position in the Thyroid Eye Disease space. The deal is likely to be seen as a strategic move to strengthen Amgen's product offerings.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Xeris Biopharma could benefit financially from the agreement with Amgen, with the potential to receive up to $75M in milestones.
The exclusive license agreement with Amgen is a significant development for Xeris, potentially bringing in substantial milestone payments. This news is likely to be viewed positively by investors, as it not only provides a financial boost but also validates Xeris's Xeriject technology.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100